Literature DB >> 15124219

Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination.

Leonid M Berezhkovskiy1.   

Abstract

The problem of finding the steady-state volume of distribution V(ss) for a linear pharmacokinetic system with peripheral drug elimination is considered. A commonly used equation V(ss) = (D/AUC)*MRT is applicable only for the systems with central (plasma) drug elimination. The following equation, V(ss) = (D/AUC)*MRT(int), was obtained, where AUC is the commonly calculated area under the time curve of the total drug concentration in plasma after intravenous (iv) administration of bolus drug dose, D, and MRT(int) is the intrinsic mean residence time, which is the average time the drug spends in the body (system) after entering the systemic circulation (plasma). The value of MRT(int) cannot be found from a drug plasma concentration profile after an iv bolus drug input if a peripheral drug exit occurs. The obtained equation does not contain the assumption of an immediate equilibrium of protein and tissue binding in plasma and organs, and thus incorporates the rates of all possible reactions. If drug exits the system only through central compartment (plasma) and there is an instant equilibrium between bound and unbound drug fractions in plasma, then MRT(int) becomes equal to MRT = AUMC/AUC, which is calculated using the time course of the total drug concentration in plasma after an iv bolus injection. Thus, the obtained equation coincides with the traditional one, V(ss) = (D/AUC)*MRT, if the assumptions for validity of this equation are met. Experimental methods for determining the steady-state volume of distribution and MRT(int), as well as the problem of determining whether peripheral drug elimination occurs, are considered. The equation for calculation of the tissue-plasma partition coefficient with the account of peripheral elimination is obtained. The difference between traditionally calculated V(ss) = (D/AUC)*MRT and the true value given by (D/AUC)*MRT(int) is discussed. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1628-1640, 2004

Mesh:

Year:  2004        PMID: 15124219     DOI: 10.1002/jps.20073

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  77 in total

1.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

Review 2.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

3.  Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.

Authors:  Max von Kleist; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-25       Impact factor: 2.745

4.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

5.  Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound.

Authors:  Yejin Esther Yun; Cecilia A Cotton; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-21       Impact factor: 2.745

6.  Physiologically Based Pharmacokinetics of Dexamethasone in Rats.

Authors:  Dawei Song; Le Sun; Debra C DuBois; Richard R Almon; Shengnan Meng; William J Jusko
Journal:  Drug Metab Dispos       Date:  2020-06-29       Impact factor: 3.922

7.  Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.

Authors:  Hannah M Jones; Iain B Gardner; Wendy T Collard; Phil J Stanley; Penny Oxley; Natilie A Hosea; David Plowchalk; Steve Gernhardt; Jing Lin; Maurice Dickins; S Ravi Rahavendran; Barry C Jones; Kenny J Watson; Henry Pertinez; Vikas Kumar; Susan Cole
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

8.  Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.

Authors:  Xuan Ding; Ivelina Gueorguieva; James A Wesley; Lee J Burns; Carrie A Coutant
Journal:  AAPS J       Date:  2015-07-01       Impact factor: 4.009

9.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

10.  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Authors:  Nikunjkumar Patel; Oliver Hatley; Alexander Berg; Klaus Romero; Barbara Wisniowska; Debra Hanna; David Hermann; Sebastian Polak
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.